Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.002
Sell
RSI(14)
37.245
Neutral
STOCH(KDJ)(9,3,3)
16.241
Neutral
ATR(14)
0.043
Low Volatility
CCI(14)
-184.318
Sell
Williams %R
82.853
Oversold
TRIX(12,20)
-0.552
Sell
StochRSI(14)
36.130
Buy
Search
Curis Inc
CRISAdd to Watchlist
0.513USD
+0.013+2.66%
Close 05/14, 16:00（ET）Quotes delayed by 15 min
20.01MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Curis Inc
Currency: USD Updated: 2026-05-13Key Insights
Curis Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 157 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Curis Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Curis Inc Highlights
StrengthsRisks
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.44M.
Fairly Valued
The company’s latest PE is -0.87, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 9.82M shares, increasing 31.37% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 240.92K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.09.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
14.000
Target Price
+2440.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-13The current financial score of Curis Inc is 7.69, ranking 65 out of 383 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high.
Score
Financials
5.17
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.55
Operational Efficiency
10.00
Growth Potential
8.35
Shareholder Returns
7.36
Curis Inc's Company Valuation
Currency: USD Updated: 2026-05-13The current valuation score of Curis Inc is 6.80, ranking 210 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.87, which is -78.00% below the recent high of -0.19 and -124.62% above the recent low of -1.95.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 157/383
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-13The current earnings forecast score of Curis Inc is 8.00, ranking 161 out of 383 in the Biotechnology & Medical Research industry. The average price target is 17.00, with a high of 20.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
14.000
Target Price
+2440.83%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Curis Inc
CRIS
4
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-13The current price momentum score of Curis Inc is 4.62, ranking 340 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.66 and the support level at 0.41, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.535
Sell
MA10
0.561
Sell
MA20
0.579
Sell
MA50
0.666
Sell
MA100
0.829
Sell
MA200
1.174
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-13The current institutional shareholding score of Curis Inc is 3.00, ranking 193 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 24.60%, representing a quarter-over-quarter decrease of 37.31%. The largest institutional shareholder is James Simons, holding a total of 240.92K shares, representing 0.60% of shares outstanding, with 34.92% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Stonepine Capital Management, LLC
Bleichroeder LP
Satterfield (Thomas A Jr)
Armistice Capital LLC
M28 Capital Management LP
CM Management, LLC
Dentzer (James E)
1
2
Risk Assessment
Currency: USD Updated: 2026-05-13The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Curis Inc is 1.96, ranking 253 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 3.08. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
3.06
VaR
+8.13%
240-Day Maximum Drawdown
+82.15%
240-Day Volatility
+107.05%
Return
Best Daily Return
60 days
+24.00%
120 days
+24.00%
5 years
+38.56%
Worst Daily Return
60 days
-17.15%
120 days
-17.15%
5 years
-33.33%
Sharpe Ratio
60 days
-2.70
120 days
-1.56
5 years
-0.87
Risk Assessment
Maximum Drawdown
240 days
+82.15%
3 years
+97.13%
5 years
+99.72%
Return-to-Drawdown Ratio
240 days
-0.96
3 years
-0.33
5 years
-0.20
Skewness
240 days
+0.36
3 years
+0.99
5 years
+0.60
Volatility
Realised Volatility
240 days
+107.05%
5 years
+108.07%
Standardised True Range
240 days
+22.38%
5 years
+307.63%
Downside Risk-Adjusted Return
120 days
-246.83%
240 days
-246.83%
Maximum Daily Upside Volatility
60 days
+80.08%
Maximum Daily Downside Volatility
60 days
+62.00%
Liquidity
Average Turnover Rate
60 days
+4.02%
120 days
+4.34%
5 years
--
Turnover Deviation
20 days
+205.08%
60 days
+123.22%
120 days
+141.28%
Peer Comparison
Biotechnology & Medical Research
Curis Inc
CRIS
5.96 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
